Evidence map›Paper›PMID 40951241›Full record

ArticleCureus2025

Unmasking Sapovirus: Chronic Enteritis in an Immunocompromised Adult With Hypogammaglobulinemia.

Alan Wang, John Greene

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alan WangOsteopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Clearwater, USA.
John GreeneInfectious Diseases, Moffitt Cancer Center, Tampa, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sapovirus is a recognized cause of acute viral gastroenteritis, predominantly affecting children and older adults. While typically self-limiting in immunocompetent individuals, sapovirus can result in persistent, severe gastrointestinal illness in immunocompromised patients. Chronic sapovirus enteritis remains underrecognized and lacks standardized treatment guidelines. We report the case of a 69-year-old woman with multiple myeloma and profound hypogammaglobulinemia secondary to chimeric antigen receptor (CAR) T-cell therapy who presented with a 10-month history of chronic watery diarrhea. Imaging revealed features of chronic enteritis, and stool polymerase chain reaction (PCR) identified persistent sapovirus shedding. Endoscopic biopsy showed epithelial apoptosis with histologic features mimicking grade 1 graft-versus-host disease (GVHD) in the absence of prior transplantation. The patient failed to respond to corticosteroids and intravenous immunoglobulin (IVIG). She was subsequently treated with nitazoxanide, resulting in marked clinical improvement, weight gain, and complete clearance of viral shedding at follow-up. She was discharged home on a regimen of monthly IVIG and pegfilgrastim for immune support. This case highlights the challenges in diagnosing and managing chronic sapovirus enteritis in immunocompromised hosts. Impaired mucosal immunity, particularly immunoglobulin A (IgA) deficiency, likely contributes to viral persistence. Histologic findings may mimic GVHD-like injury, further complicating diagnosis. While no Food and Drug Administration (FDA)-approved treatments exist, therapies such as nitazoxanide and immunoglobulin may offer benefit; however, these observations remain exploratory and require further study in larger cohorts.

Indexed as

chronic diarrheachronic sapovirus enteritisimmunocompromisednitazoxanideviral gastroenteritis

Identifiers

PMID40951241
PMCPMC12433061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.